Effect of early-stage human breast carcinoma on monocyte programming

• Verfasst von: Patysheva, Marina [VerfasserIn]
• Verfasst von: Larionova, Irina [VerfasserIn]
• Verfasst von: Stakheyeva, Marina [VerfasserIn]
• Verfasst von: Grigoryeva, Evgeniya [VerfasserIn]
• Verfasst von: Iamshchikov, Pavel [VerfasserIn]
• Verfasst von: Tarabanovskaya, Natalia [VerfasserIn]
• Verfasst von: Weiß, Christel [VerfasserIn]
• Verfasst von: Kardashova, Julia [VerfasserIn]
• Verfasst von: Frolova, Anastasia [VerfasserIn]
• Verfasst von: Rakina, Militsa [VerfasserIn]
• Verfasst von: Prostakishina, Elizaveta [VerfasserIn]
• Verfasst von: Zhuikova, Lilia [VerfasserIn]
• Verfasst von: Cherdyntseva, Nadezhda [VerfasserIn]
• Verfasst von: Kzhyshkowska, Julia [VerfasserIn]
• Titel: Effect of early-stage human breast carcinoma on monocyte programming
• Verf.angabe: Marina Patysheva, Irina Larionova, Marina Stakheyeva, Evgeniya Grigoryeva, Pavel Iamshchikov, Natalia Tarabanovskaya, Christel Weiss, Julia Kardashova, Anastasia Frolova, Militsa Rakina, Elizaveta Prostakishina, Lilia Zhuikova, Nadezhda Cherdyntseva and Julia Kzhyshkowska
• E-Jahr: 2022
• Jahr: 14 February 2022
• Umfang: 12 S.
• Fussnoten: Gesehen am 04.03.2022
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2022
• Band/Heft Quelle: 11(2022) vom: 14. Feb., Artikel-ID 800235, Seite 1-12
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2021.800235
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1794781110
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Circulating monocytes are a major source of tumor-associated macrophages (TAMs). TAMs in human breast cancer (BC) support primary tumor growth and metastasis. Neoadjuvant chemotherapy (NAC) is a commonly used treatment for BC patients. The absence of the response to NAC has major negative consequences for the patient: increase of tumor mass, delayed surgery, and unnecessary toxicity. We aimed to identify the effect of BC on the subpopulation content and transcriptome of circulating monocytes. We examined how monocyte phenotypes correlate with the response to NAC. The percentage of CD14-, CD16-, CD163-, and HLA-DR-expressing monocytes was quantified by flow cytometry for patients with T1-4N0-3M0 before NAC. The clinical efficacy of NAC was assessed by RECIST criteria of RECIST 1.1 and by the pathological complete response (pCR). The percentage of CD14+ and СD16+ monocytes did not differ between healthy women and BC patients and did not differ between NAC responders and non-responders. The percentage of CD163-expressing CD14lowCD16+ and CD14+CD16+ monocytes was increased in BC patients compared to healthy women (99.08% vs. 60.00%, p = 0.039, and 98.08% vs. 86.96%, p = 0.046, respectively). Quantitative immunohistology and confocal microscopy demonstrated that increased levels of CD163+ monocytes are recruited in the tumor after NAC. The percentage of CD14lowCD16+ in the total monocyte population positively correlated with the response to NAC assessed by pCR: 8.3% patients with pCR versus 2.5% without pCR (p = 0.018). Search for the specific monocyte surface markers correlating with NAC response evaluated by RECIST 1.1 revealed that patients with no response to NAC had a significantly lower amount of CD14lowCD16+HLA-DR+ cells compared to the patients with clinical response to NAC (55.12% vs. 84.62%, p = 0.005). NGS identified significant changes in the whole transcriptome of monocytes of BC patients. Regulators of inflammation and monocyte migration were upregulated, and genes responsible for the chromatin remodeling were suppressed in monocyte BC patients. In summary, our study demonstrated that presence of BC before distant metastasis is detectable, significantly effects on both monocyte phenotype and transcriptome. The most striking surface markers were CD163 for the presence of BC, and HLA-DR (CD14lowCD16+HLA-DR+) for the response to NAC.